Remdesivir, the antiviral drug Gilead sells under the brand name Veklury, reduced mortality rates in hospitalized COVID-19 patients and increased their likelihood of being discharged by day 28 after a five-day regimen, Gilead said June 21.
The announcement is based on three retrospective studies examining the real-world treatment of 98,654 hospitalized COVID-19 patients.
In two of the studies, remdesivir reduced patients’ mortality risk by 54 percent and 23 percent.
Remdesivir became the first FDA-approved COVID-19 treatment in October.
A coalition of 39 state attorneys general called on Congress to pass legislation prohibiting pharmacy benefit managers and parent companies…
The FDA has approved Dupixent as the first new targeted therapy in over ten years for chronic spontaneous urticaria in…
Commonly prescribed medications such as statins, non-steroidal anti-inflammatory drugs and certain blood pressure drugs may significantly delay the onset of…
Comments are closed.
